0.36 MB - Italian Journal of Public Health

I T A L I A N J O U R N A L O F P U B L I C H E A L T H
of the pneumococcal conjugate vaccine on drug-resistant
Streptococcus pneumoniae. N Engl J Med 2006;354(14):1455-
63.
5) Reinert RR. Resistance phenotypes and multi-drug resistance
in Streptococcus pneumoniae. J Chemother 2004;16(Suppl
6):35-48.
6) Hicks LA, Harrison LH, Flannery B, et al. Incidence of
pneumococcal disease due to non-pneumococcal conjugate
vaccine (PCV7) serotypes in the United States during the
era of widespread PCV7 vaccination, 1998-2004. J Infect Dis
2007;196(9):1346-54.
7) Jacobs R, Jacobs MR, Kaplan SL. Pneumococcal disease caused
by serotype 19A: Review of the literature and implications for
future vaccine development. Vaccine 2010 Apr 20.
8) Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia
JJ, Pallares R. Emergence of invasive pneumococcal disease
caused by nonvaccine serotypes in the era of 7-valent conjugate
vaccine. Clin Infect Dis. 2008;46(2):174-82.
9) Pichichero ME, Casey JR. Evolving microbiology
and molecular epidemiology of acute otitis media in the
pneumococcal conjugate vaccine era. Pediatr Infect Dis J
2007;26(10 Suppl):S12-6.
10) Choi EH, Kim SH, Eun BW, et al. Streptococcus pneumoniae
serotype 19A in children, South Korea. Emerg Infect Dis. 2008
Feb;14(2):275-81.
11) Camilli R, D’ambrosio F, Pantosti A. Come è cambiata
l’epidemiologia delle infezioni da pneumococco con
l’introduzione del vaccino pediatrico? Riv Immunologia
Allergologia Pediatrica 2009; 3:1-8.
12) Gherardi G, D’Ambrosio F, Monaco M, et al. Population
structure of invasive Streptococcus pneumoniae isolates in Italy
prior to the implementation of the 7-valent conjugate vaccine
(1999-2003). Eur J Clin Microbiol Infect Dis 2009;28(1):99-103.
13) Schito GC, Palù G, Fadda G, Pozzi G, Barbara C, Nicoletti
G, et al. Streptococcus pneumoniae as a cause of invasive
infections in all ages in Italy: serotypes and pattern of
antibiotics resistance. Giornale Italiano Microbiologia Medica
IJPH - Year 8, Volume 7, Number 2, Suppl. 1, 2010
Odontoiatrica e Clinica 2009; XIII (1): 1-21.
14) WHO. Recommendations for production and control of
pneumococcal coniugate vaccines. WHO Technical Report
Series 2005;927.
15) WHO. Challenger in evaluation and licensing of new
pneumococcal coniugate vaccines. Vaccine 2009; 27: 3681-8.
16) Klinger CL, Snape LD, John T, et al., Immunogenicity of
DTaP-IPV-Hib and MenC vaccines in UK when administered
with a 13-valent pneumococcal coniugate vaccine. Interscience
Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) e della Infectious Diseases Society of America (IDSA) a
Washington, DC negli Stati Uniti. 25-27 Ottobre 2008.
17) Klieninger DM, Kueper K, Steul K et al. Safety and
immunologic non-inferiority of 13-valent Pneumococcal
Coniugate Vaccine compared to 7-valent Pneumococcal
Conjugate Vaccine given as a 4-dose series with routine vaccines
in healthy infants and toddlers. Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC) and
Infectious Diseases Society of America (IDSA) . Washington,
DC, Stati Uniti. 25-27 Ottobre 2008.
18) Grimpel E, Scott D, Laudat F et al. Safety and immunogenicity
of a 13-valent pneumococcal coniugate vaccine given with
routine pediatric vaccination in healthy infants in France.
Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) Infectious Diseases Society of America
(IDSA) a Washington, DC, Stati Uniti. 25-27 Ottobre 2008.
19) Esposito S, Tansey S, Thompson A et al. Safety and
immunologic non-inferiority of 13-valent Pneumococcal
Coniugate Vaccine compared to 7-valent Pneumococcal
Conjugate Vaccine given as a 3-dose series with routine
vaccines in healthy children in Italy. Poster Congresso ESPID,
Bruxelles, maggio 2009.
20) Grimpel E, Laudat F, Baker SA, et al. Safety and
immunogenicity of a 13-valent pneumococcal coniugate
vaccine given with routine pediatric vaccination to healthy
children in France. Poster Congresso ESPID, Bruxelles, maggio
2009.
C A P I T O L O 4 S 3 5